Scarica l'app Stockscreener
5.88
0.51%
-0.03
Pre-mercato:
6.03
0.15
+2.55%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché IOVA Giù?
Forum
Previsione
Frazionamento azionario
Iovance Biotherapeutics Inc Borsa (IOVA) Ultime notizie
(IOVA) Technical Pivots with Risk Controls - Stock Traders Daily
Iovance Biotherapeutics (NASDAQ:IOVA) Sets New 52-Week LowHere's Why - MarketBeat
Cervical Cancer Market Expected to Experience Major Growth - openPR
Billionaire Joseph Edelman’s Top 10 Long-Term Stock Picks - Insider Monkey
Is Iovance Biotherapeutics (IOVA) Among Billionaire Joseph Edelman’s Long-Term Stock Picks? - Yahoo Finance
1,746,877 Shares in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Purchased by Assenagon Asset Management S.A. - MarketBeat
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
Iovance Biotherapeutics Awards 224,550 Stock Options to Expand Team with 41 New Hires - StockTitan
First Week of September 19th Options Trading For Iovance Biotherapeutics (IOVA) - Nasdaq
Iovance Biotherapeutics (NASDAQ:IOVA) Sets New 1-Year LowTime to Sell? - MarketBeat
Oversold Conditions For Iovance Biotherapeutics (IOVA) - Nasdaq
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) May Have Run Too Fast Too Soon With Recent 25% Price Plummet - Simply Wall St
How To Trade (IOVA) - Stock Traders Daily
Cancer Drug Maker Iovance Tumbles Toward Worst Week Since November, But Retail Feels Macro Selloff Overblown - MSN
Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price Down 7.8%Here's Why - MarketBeat
Iovance Biotherapeutics Shares Are Falling Today: What's Going On? - Benzinga
Immunotoxins Market Trends and Regional Business Opportunities, 2024-2034: Diphtheria Toxin-Based Immunotoxins Lead Revenue, Pseudomonas Exotoxins Show Rapid Growth Potential - GlobeNewswire Inc.
Iovance Biotherapeutics (IOVA) Surges on Positive Analyst Outloo - GuruFocus.com
Why Iovance Biotherapeutics Stock Zoomed More Than 5% Higher Today - MSN
Stifel maintains Buy on Iovance Biotherapeutics stock, optimistic on Amtagvi By Investing.com - Investing.com Canada
Iovance Biotherapeutics (NASDAQ:IOVA) Shares Up 7.7%What's Next? - MarketBeat
Why Iovance Biotherapeutics Inc. (IOVA) Is Skyrocketing - MSN
Analysts Set Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Price Target at $23.00 - MarketBeat
Philly’s year in biopharma: a look back at 2024 - The Philadelphia Inquirer
The Immunotherapy Boom: What It Means for the Future of Cancer Treatment - Baystreet.ca
Principal Financial Group Inc. Has $37.87 Million Stake in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - MarketBeat
Geode Capital Management LLC Cuts Position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - MarketBeat
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares Purchased by Barclays PLC - MarketBeat
Where are the Opportunities in (IOVA) - Stock Traders Daily
Insiders' US$48.3m Investments In Red Following Iovance Biotherapeutics' US$402m Dip In Market Value - Simply Wall St
Iovance Biotherapeutics is Now Oversold (IOVA) - Nasdaq
KEI Comments on NIH Exclusive License to Iovance for T-cell Vaccine for Cancer Treatment - Knowledge Ecology International
Iovance Biotherapeutics: Amtagvi Launch Growing, But Stock Isn't (NASDAQ:IOVA) - Seeking Alpha
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Sees Significant Increase in Short Interest - MarketBeat
State Street Corp Grows Holdings in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - MarketBeat
Iovance Biotherapeutics' SWOT analysis: promising TIL therapy stock faces growth hurdles - Investing.com India
Interesting IOVA Call Options For January 2025 - Nasdaq
Prediction: This Stock Will Beat the Market in 2025 - Yahoo Finance
BNP Paribas Financial Markets Trims Stock Holdings in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - MarketBeat
Iovance Biotherapeutics' SWOT analysis: stock shows promise amid challenges By Investing.com - Investing.com Nigeria
Iovance Biotherapeutics: Steady Progress (NASDAQ:IOVA) - Seeking Alpha
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
4.81%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):